Get access to our best features

Get access to our best features

Published 2 months ago

Ionis stock jumps as MASH drug succeeds in mid-stage trial (NASDAQ:IONS)

Summary by Ground News

Ionis Pharmaceuticals (IONS) shares rose in early trading on Wednesday. The company reported positive results from a mid-stage trial of its investigational drug. ION224 is an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis.

0 Articles

0 Articles

All

Left

Center

Right

Ionis stock jumps as MASH drug succeeds in mid-stage trial (NASDAQ:IONS)

Ionis Pharmaceuticals reported positive results from a Phase 2 study of its investigational drug for fatty liver disease.

2 months ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right1Center0Last Updated2 months agoBias Distribution

100% Right

Bias Distribution

100% of the sources lean Right

100% Right

Seeking Alpha

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.